Concepts (268)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumococcal Infections | 9 | 2025 | 299 | 2.280 |
Why?
|
| Immunization, Secondary | 6 | 2025 | 72 | 2.200 |
Why?
|
| Streptococcal Infections | 12 | 2023 | 184 | 2.150 |
Why?
|
| Immunoglobulin G | 14 | 2025 | 231 | 2.110 |
Why?
|
| Antibodies, Bacterial | 16 | 2025 | 153 | 2.080 |
Why?
|
| Pneumococcal Vaccines | 8 | 2025 | 278 | 2.030 |
Why?
|
| Vaccines | 5 | 2024 | 86 | 1.500 |
Why?
|
| Streptococcus pneumoniae | 7 | 2025 | 336 | 1.410 |
Why?
|
| Infant | 37 | 2025 | 2244 | 1.400 |
Why?
|
| Serogroup | 7 | 2025 | 150 | 1.330 |
Why?
|
| Immunization Schedule | 5 | 2025 | 81 | 1.330 |
Why?
|
| Humans | 75 | 2025 | 14537 | 1.260 |
Why?
|
| Streptococcus agalactiae | 14 | 2024 | 202 | 1.190 |
Why?
|
| Female | 53 | 2025 | 9103 | 1.000 |
Why?
|
| Hospitalization | 6 | 2024 | 418 | 0.980 |
Why?
|
| Influenza, Human | 4 | 2023 | 374 | 0.940 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2024 | 529 | 0.940 |
Why?
|
| South Africa | 37 | 2025 | 7596 | 0.900 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2024 | 200 | 0.880 |
Why?
|
| Respiratory Tract Infections | 2 | 2024 | 266 | 0.870 |
Why?
|
| Immunogenicity, Vaccine | 6 | 2025 | 103 | 0.870 |
Why?
|
| Vaccines, Conjugate | 6 | 2025 | 171 | 0.820 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2024 | 155 | 0.790 |
Why?
|
| HIV Infections | 21 | 2024 | 5097 | 0.760 |
Why?
|
| Male | 36 | 2025 | 6754 | 0.760 |
Why?
|
| Pregnancy | 20 | 2024 | 1862 | 0.760 |
Why?
|
| Bayes Theorem | 6 | 2023 | 81 | 0.750 |
Why?
|
| Mycobacterium tuberculosis | 4 | 2016 | 329 | 0.720 |
Why?
|
| Vaccination | 11 | 2023 | 365 | 0.690 |
Why?
|
| Child, Preschool | 15 | 2024 | 1748 | 0.600 |
Why?
|
| Models, Statistical | 2 | 2022 | 55 | 0.570 |
Why?
|
| Pandemics | 4 | 2023 | 296 | 0.560 |
Why?
|
| Tuberculosis | 5 | 2020 | 543 | 0.550 |
Why?
|
| Infant, Newborn | 18 | 2024 | 1479 | 0.550 |
Why?
|
| Child | 17 | 2023 | 2242 | 0.530 |
Why?
|
| Pneumonia | 1 | 2017 | 131 | 0.510 |
Why?
|
| Antibodies, Viral | 9 | 2023 | 284 | 0.500 |
Why?
|
| Specimen Handling | 3 | 2019 | 105 | 0.470 |
Why?
|
| Antibodies, Neutralizing | 5 | 2023 | 303 | 0.450 |
Why?
|
| Models, Biological | 1 | 2013 | 77 | 0.420 |
Why?
|
| Retrospective Studies | 13 | 2024 | 799 | 0.420 |
Why?
|
| Nasopharynx | 3 | 2024 | 151 | 0.390 |
Why?
|
| Models, Genetic | 1 | 2011 | 13 | 0.380 |
Why?
|
| Anti-Retroviral Agents | 4 | 2020 | 551 | 0.380 |
Why?
|
| Case-Control Studies | 7 | 2022 | 480 | 0.370 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 293 | 0.350 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2013 | 226 | 0.350 |
Why?
|
| Streptococcal Vaccines | 2 | 2023 | 47 | 0.340 |
Why?
|
| Antitubercular Agents | 1 | 2013 | 322 | 0.340 |
Why?
|
| Adult | 23 | 2024 | 5913 | 0.340 |
Why?
|
| Adolescent | 18 | 2021 | 2985 | 0.310 |
Why?
|
| Neoplasms | 2 | 2020 | 147 | 0.310 |
Why?
|
| Hepatitis B Vaccines | 3 | 2018 | 40 | 0.310 |
Why?
|
| Stillbirth | 4 | 2024 | 83 | 0.290 |
Why?
|
| Incidence | 8 | 2023 | 685 | 0.270 |
Why?
|
| Prospective Studies | 8 | 2024 | 1160 | 0.270 |
Why?
|
| Bacterial Capsules | 3 | 2015 | 33 | 0.270 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2024 | 101 | 0.270 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2018 | 28 | 0.270 |
Why?
|
| Seasons | 4 | 2020 | 154 | 0.270 |
Why?
|
| Polysaccharides, Bacterial | 2 | 2016 | 35 | 0.270 |
Why?
|
| Cause of Death | 4 | 2019 | 221 | 0.260 |
Why?
|
| Hospitals | 2 | 2023 | 103 | 0.260 |
Why?
|
| Influenza Vaccines | 2 | 2020 | 144 | 0.260 |
Why?
|
| Immunization Programs | 2 | 2017 | 81 | 0.260 |
Why?
|
| Databases, Factual | 2 | 2017 | 64 | 0.250 |
Why?
|
| Network Meta-Analysis | 1 | 2024 | 8 | 0.230 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2024 | 3 | 0.230 |
Why?
|
| Young Adult | 10 | 2021 | 2498 | 0.230 |
Why?
|
| Postpartum Period | 1 | 2024 | 85 | 0.230 |
Why?
|
| Carrier State | 3 | 2024 | 92 | 0.230 |
Why?
|
| Polysaccharides | 2 | 2024 | 45 | 0.220 |
Why?
|
| Pesticides | 1 | 2023 | 4 | 0.220 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 253 | 0.220 |
Why?
|
| Maternal Death | 1 | 2024 | 25 | 0.220 |
Why?
|
| Coinfection | 2 | 2024 | 276 | 0.220 |
Why?
|
| Sepsis | 2 | 2022 | 102 | 0.220 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 38 | 0.210 |
Why?
|
| Immunologic Memory | 2 | 2020 | 15 | 0.210 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2017 | 324 | 0.210 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 42 | 0.210 |
Why?
|
| Antibody Formation | 3 | 2021 | 61 | 0.200 |
Why?
|
| Cohort Studies | 6 | 2020 | 967 | 0.200 |
Why?
|
| Poverty | 2 | 2020 | 152 | 0.190 |
Why?
|
| Brain Diseases | 1 | 2022 | 24 | 0.190 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 73 | 0.190 |
Why?
|
| Patient Discharge | 1 | 2021 | 27 | 0.180 |
Why?
|
| Bacteria | 1 | 2021 | 47 | 0.180 |
Why?
|
| Neonatal Sepsis | 1 | 2021 | 29 | 0.180 |
Why?
|
| Unemployment | 1 | 2020 | 10 | 0.180 |
Why?
|
| Financing, Government | 1 | 2020 | 11 | 0.180 |
Why?
|
| Femur | 1 | 2020 | 11 | 0.180 |
Why?
|
| Gender-Based Violence | 1 | 2020 | 12 | 0.180 |
Why?
|
| Slipped Capital Femoral Epiphyses | 1 | 2020 | 2 | 0.180 |
Why?
|
| Bone Diseases, Developmental | 1 | 2020 | 8 | 0.180 |
Why?
|
| Osteochondrosis | 1 | 2020 | 8 | 0.180 |
Why?
|
| Developing Countries | 2 | 2020 | 400 | 0.170 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 54 | 0.170 |
Why?
|
| Bacterial Infections | 1 | 2020 | 54 | 0.170 |
Why?
|
| Immunity, Maternally-Acquired | 2 | 2023 | 40 | 0.170 |
Why?
|
| Haemophilus influenzae type b | 1 | 2020 | 17 | 0.170 |
Why?
|
| Milk, Human | 1 | 2020 | 23 | 0.170 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 101 | 0.160 |
Why?
|
| Double-Blind Method | 7 | 2021 | 272 | 0.160 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 27 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 71 | 0.160 |
Why?
|
| Immunization | 1 | 2019 | 63 | 0.160 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 55 | 0.160 |
Why?
|
| Middle Aged | 11 | 2021 | 3601 | 0.160 |
Why?
|
| Nutritional Status | 1 | 2019 | 76 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 104 | 0.160 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 65 | 0.150 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2017 | 1 | 0.150 |
Why?
|
| Glasgow Coma Scale | 1 | 2017 | 4 | 0.150 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2015 | 42 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 239 | 0.140 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2017 | 21 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 30 | 0.140 |
Why?
|
| Age Distribution | 1 | 2017 | 107 | 0.140 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2016 | 10 | 0.140 |
Why?
|
| Bacterial Adhesion | 1 | 2016 | 6 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 25 | 0.130 |
Why?
|
| Aged | 7 | 2021 | 1740 | 0.130 |
Why?
|
| Gestational Age | 3 | 2022 | 80 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2015 | 11 | 0.130 |
Why?
|
| Mutation | 2 | 2021 | 306 | 0.130 |
Why?
|
| Rotavirus Infections | 1 | 2016 | 46 | 0.130 |
Why?
|
| Diarrhea | 1 | 2016 | 76 | 0.130 |
Why?
|
| Rotavirus Vaccines | 1 | 2016 | 53 | 0.120 |
Why?
|
| Haemophilus Infections | 1 | 2015 | 23 | 0.120 |
Why?
|
| Pilot Projects | 3 | 2019 | 179 | 0.120 |
Why?
|
| Autopsy | 3 | 2019 | 140 | 0.120 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 31 | 0.120 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2014 | 14 | 0.110 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 10 | 0.110 |
Why?
|
| Haemophilus Vaccines | 1 | 2014 | 41 | 0.110 |
Why?
|
| Markov Chains | 1 | 2013 | 22 | 0.110 |
Why?
|
| Seroepidemiologic Studies | 2 | 2023 | 109 | 0.100 |
Why?
|
| Computational Biology | 1 | 2013 | 44 | 0.100 |
Why?
|
| Age Factors | 4 | 2020 | 370 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 198 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 244 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2011 | 56 | 0.090 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 37 | 0.090 |
Why?
|
| Fetal Blood | 2 | 2022 | 27 | 0.090 |
Why?
|
| United Kingdom | 2 | 2020 | 33 | 0.090 |
Why?
|
| Haemophilus influenzae | 2 | 2023 | 42 | 0.090 |
Why?
|
| Immunoassay | 2 | 2024 | 28 | 0.080 |
Why?
|
| Staphylococcus aureus | 2 | 2023 | 43 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1422 | 0.080 |
Why?
|
| Viral Envelope Proteins | 2 | 1999 | 6 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 1324 | 0.080 |
Why?
|
| Viral Vaccines | 2 | 1999 | 24 | 0.080 |
Why?
|
| Perinatal Death | 2 | 2019 | 33 | 0.080 |
Why?
|
| Risk Factors | 3 | 2020 | 1475 | 0.080 |
Why?
|
| Prenatal Care | 2 | 2019 | 147 | 0.070 |
Why?
|
| Prevalence | 3 | 2016 | 1192 | 0.070 |
Why?
|
| Time Factors | 3 | 2018 | 507 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 435 | 0.070 |
Why?
|
| HIV-1 | 1 | 2015 | 1260 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 48 | 0.060 |
Why?
|
| Solvents | 1 | 2023 | 15 | 0.060 |
Why?
|
| Biomarkers | 2 | 2015 | 327 | 0.060 |
Why?
|
| Receptors, Fc | 1 | 2023 | 10 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 151 | 0.050 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 34 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 217 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 1993 | 39 | 0.050 |
Why?
|
| Ribs | 1 | 2023 | 4 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2023 | 9 | 0.050 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2023 | 7 | 0.050 |
Why?
|
| Botswana | 1 | 2023 | 24 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 39 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2023 | 36 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 2 | 1999 | 23 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 60 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2021 | 175 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 44 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 39 | 0.050 |
Why?
|
| Safety | 1 | 2021 | 34 | 0.050 |
Why?
|
| Vaccine Potency | 1 | 2021 | 16 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2020 | 17 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2021 | 39 | 0.050 |
Why?
|
| Brazil | 1 | 2020 | 47 | 0.050 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 34 | 0.050 |
Why?
|
| Hemagglutinins | 1 | 2020 | 5 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 34 | 0.040 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2020 | 13 | 0.040 |
Why?
|
| London | 1 | 2020 | 8 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 62 | 0.040 |
Why?
|
| Child Health Services | 1 | 2020 | 35 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 52 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2020 | 89 | 0.040 |
Why?
|
| Animals | 2 | 2020 | 1081 | 0.040 |
Why?
|
| Maternal Health Services | 1 | 2020 | 52 | 0.040 |
Why?
|
| Diagnosis | 1 | 2019 | 7 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2019 | 13 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 13 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 1999 | 24 | 0.040 |
Why?
|
| Vaccines, Inactivated | 2 | 2015 | 23 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 1999 | 12 | 0.040 |
Why?
|
| Pertussis Vaccine | 1 | 1999 | 16 | 0.040 |
Why?
|
| Taxes | 1 | 2020 | 73 | 0.040 |
Why?
|
| Placenta | 1 | 2019 | 44 | 0.040 |
Why?
|
| Polysorbates | 1 | 1999 | 10 | 0.040 |
Why?
|
| Squalene | 1 | 1999 | 10 | 0.040 |
Why?
|
| Vitamin D | 1 | 2019 | 41 | 0.040 |
Why?
|
| Herpesvirus 2, Human | 1 | 1999 | 43 | 0.040 |
Why?
|
| Gambia | 1 | 2019 | 13 | 0.040 |
Why?
|
| Placenta Diseases | 1 | 2019 | 5 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 124 | 0.040 |
Why?
|
| Herpes Genitalis | 1 | 1999 | 43 | 0.040 |
Why?
|
| Birth Weight | 1 | 2019 | 80 | 0.040 |
Why?
|
| Infant Mortality | 1 | 2019 | 97 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 167 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 56 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 370 | 0.040 |
Why?
|
| Antibodies | 1 | 2018 | 25 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2019 | 87 | 0.040 |
Why?
|
| Algorithms | 1 | 2019 | 106 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 889 | 0.040 |
Why?
|
| Hepatitis B | 1 | 1999 | 125 | 0.040 |
Why?
|
| Prognosis | 1 | 2017 | 199 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 188 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2016 | 10 | 0.030 |
Why?
|
| Bacteremia | 1 | 2017 | 79 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2016 | 28 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 468 | 0.030 |
Why?
|
| Rectum | 1 | 2016 | 22 | 0.030 |
Why?
|
| Fimbriae, Bacterial | 1 | 2015 | 10 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 2015 | 12 | 0.030 |
Why?
|
| Vagina | 1 | 2016 | 91 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2015 | 23 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 87 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2015 | 32 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 2014 | 4 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 227 | 0.030 |
Why?
|
| Hypertension | 1 | 2019 | 419 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 1993 | 9 | 0.030 |
Why?
|
| Asthma | 1 | 1993 | 33 | 0.030 |
Why?
|
| Dermatitis, Atopic | 1 | 1993 | 3 | 0.030 |
Why?
|
| Opsonin Proteins | 1 | 2012 | 4 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2012 | 15 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 150 | 0.030 |
Why?
|
| Immunoglobulin E | 2 | 1993 | 9 | 0.010 |
Why?
|
| Injections, Subcutaneous | 2 | 1993 | 22 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1993 | 73 | 0.010 |
Why?
|
| Viral Plaque Assay | 1 | 1999 | 1 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1999 | 21 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 1999 | 2 | 0.010 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1999 | 3 | 0.010 |
Why?
|
| Cricetinae | 1 | 1999 | 3 | 0.010 |
Why?
|
| CHO Cells | 1 | 1999 | 3 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 14 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 1999 | 23 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1999 | 31 | 0.010 |
Why?
|
| Placebos | 1 | 1999 | 44 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1999 | 22 | 0.010 |
Why?
|
| Bordetella pertussis | 1 | 1999 | 29 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1999 | 163 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1999 | 108 | 0.010 |
Why?
|
| Eosinophils | 1 | 1993 | 1 | 0.010 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 1993 | 2 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 1993 | 9 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1993 | 25 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1993 | 24 | 0.010 |
Why?
|
| Prednisone | 1 | 1993 | 17 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1993 | 125 | 0.010 |
Why?
|